Drug Trial Radar · NCT05571345
A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 5, 2022
Primary completion
Dec 23, 2022
Study completion Dec 28, 2022
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Dr. Vince Clinical Research
- First posted
- Oct 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential, safety and pharmacokinetics of orally administered PF614 relative to oxycodone IR (immediate-release) tablets and placebo.
Conditions
- Recreational Drug Use
Interventions
PF614Drug
PF614 capsules (50 mg or 100 mg)
Oxycodone Hydrochloride 40 mgDrug
Oral 20 mg tablets (two each)
PlaceboDrug
Placebo to match PF614 capsules will be provided by the sponsor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)Time frame: Up to 24 hour post-dose (up to Day 2)
- Take Drug Again VAS (Emax)Time frame: 12 hours post-dose
- Take Drug Again VAS (Emax)Time frame: 24 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr. Vince Clinical Research
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.